Holder Michael 4

What Happened

• Michael, a director of Cytek Biosciences (CTKB), had equity awards recorded on the Form 4 dated 2026-06-12 for activity on 2026-06-10. The filing shows two RSU awards/awards acquired (33,333 and 18,261 shares, respectively, at $0.00) totaling 51,594 RSU shares, and a derivative exercise/conversion and related disposition of 43,973 shares (both recorded at $0.00).
• In plain terms: 51,594 RSU shares were issued/acquired (these RSUs vested per the filing) and 43,973 shares were surrendered/disposed the same day. The net result recorded in the filing implies 7,621 shares were retained by the insider after the surrender (51,594 − 43,973 = 7,621). No cash amounts or sale proceeds are reported.

Key Details

• Transaction date(s): June 10, 2026; Form 4 filed June 12, 2026 (appears timely under standard 2-business-day reporting).
• Entries reported:
  • Grant/Award (A): 33,333 shares @ $0.00 (Derivative)
  • Grant/Award (A): 18,261 shares @ $0.00 (Derivative)
  • Exercise/Conversion (M): 43,973 shares acquired / 43,973 shares disposed @ $0.00 (Derivative)
• Shares owned after transaction: not explicitly stated in the excerpt of the filing; net issued to insider per the reported entries appears to be 7,621 shares.
• Relevant footnotes from the filing:
  • F1: Each RSU represents a contingent right to one share.
  • F4: 100% of the shares subject to the RSU Award vested on June 10, 2026.
  • F2/F3 note other awards/options have vesting scheduled (earlier of June 10, 2027 or the 2027 annual meeting) for certain grants/options referenced in the filing.
• The disposition of 43,973 shares is recorded but no cash consideration is shown; such dispositions are commonly (but not always explicitly) used to satisfy tax withholding obligations.

Context

• These entries are derivative-related: RSUs vested and converted into common shares (derivative → equity). The simultaneous surrender/disposition of a portion of the issued shares is typically a net settlement or withholding action rather than an open-market sale; the filing does not show proceeds from a market sale.
• This is routine insider reporting of award vesting and related share withholding; it is factual information about ownership changes and not an explicit statement of the insider’s market view.